0.39
0.39 (0%)
As of Feb 14, 2025
Organovo Holdings, Inc. [ONVO]
Source:
Company Overview
Organovo Holdings, Inc. is a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (“IBD”), including ulcerative colitis (“UC”), based on demonstration of clinical promise in three-dimensional (“3D”) human tissues as well as strong preclinical data. FXR is a mediator of gastrointestinal and liver diseases. FXR agonism has been tested in a variety of preclinical models of IBD.
| Country | United States |
| Headquarters | san diego, california |
| Phone Number | 858-224-1000 |
| Industry | manufacturing |
| CEO | Keith Murphy |
| Website | www.organovo.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-3.5 |
| Net Income | $-3.4 |
| Net Cash | $0 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | -14,450 |
| Profit as % of Revenues | -0.6% |
| Profit as % of Assets | -67.6% |
| Profit as % of Stockholder Equity | -947% |
Management Effectiveness
| Return on Equity | -947% |
| Return on Assets | -89.7% |
| Turnover Ratio | 0.5% |
| EBITA | $-3.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $3.8 |
| Total Liabilities | $3.5 |
| Operating Cash Flow | $0 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $0 |
